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Abstract
Venezuelan equine encephalitis virus (VEEV) has been responsible for hundreds of thousands of human and equine cases of
severe disease in the Americas. A passive surveillance study was conducted in Peru, Bolivia and Ecuador to determine the
arboviral etiology of febrile illness. Patients with suspected viral-associated, acute, undifferentiated febrile illness of ,7 days
duration were enrolled in the study and blood samples were obtained from each patient and assayed by virus isolation.
Demographic and clinical information from each patient was also obtained at the time of voluntary enrollment. In 2005–
2007, cases of Venezuelan equine encephalitis (VEE) were diagnosed for the first time in residents of Bolivia; the patients did
not report traveling, suggesting endemic circulation of VEEV in Bolivia. In 2001 and 2003, VEE cases were also identified in
Ecuador. Since 1993, VEEV has been continuously isolated from patients in Loreto, Peru, and more recently (2005), in Madre
de Dios, Peru. We performed phylogenetic analyses with VEEV from Bolivia, Ecuador and Peru and compared their
relationships to strains from other parts of South America. We found that VEEV subtype ID Panama/Peru genotype is the
predominant one circulating in Peru. We also demonstrated that VEEV subtype ID strains circulating in Ecuador belong to
the Colombia/Venezuela genotype and VEEV from Madre de Dios, Peru and Cochabamba, Bolivia belong to a new ID
genotype. In summary, we identified a new major lineage of enzootic VEEV subtype ID, information that could aid in the
understanding of the emergence and evolution of VEEV in South America.
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Introduction
Venezuelan equine encephalitis virus (VEEV), a member of the
family Togaviridae genus Alphavirus, has been responsible for
outbreaks involving hundreds-of-thousands of equine and human
cases of severe disease in the Americas [1]. At least 14 varieties
within the six VEE subtype complex of alphaviruses have been
recognized. Only subtype I varieties AB and C have caused major
epizootics/epidemics, whereas subtypes II through VI and subtype
I varieties D, E and F are enzootic strains that are generally
avirulent in horses, but capable of causing human disease [2].
In Ecuador, VEE was first confirmed in 1944 when the virus
was isolated from the blood of a sick horse [3]. However, clinical
cases that were compatible with VEEV infection had been
observed as early as 1940. In 1958, VEEV neutralizing antibodies
were found in sera of inhabitants of the Pacific coastal region of
Ecuador [4]. In 1968–1969, a large outbreak involving more than
30,000 equids was reported, and in 1975–1977, field work
investigations in Ecuador yielded VEEV isolates that were
characterized genetically as the Southwestern Colombia/Ecuador
ID genotype [5,6].
In Peru, VEEV was first isolated in the 1940s when subtype IAB
caused epizootics and epidemics along the Peruvian coast [7,8].
Field work investigations were conducted afterwards in the
Amazon region of Peru, resulting in the isolation of 11 VEE
complex alphavirus strains [9,10]. Ten isolates were later
identified as subtype ID VEEV, whereas one strain was identified
as a (new) subtype IIIC virus [9,10,11]. Evidence of VEEV human
infections was only obtained in 1993–1995, when subtype ID was
isolated from febrile patients residing in the Amazon region of
Peru [12,13].
In 2000, in collaboration with the Ministries of Health of
Bolivia, Ecuador and Peru, a passive surveillance study was
initiated with the purpose of investigating the etiology of febrile
illness. As part of the surveillance activities in Peru, several VEEV
strains were obtained from febrile patients. Genetic analyses of
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circulating genotypes: Colombia/Venezuela and Peru/Panama
[14,15]. In addition, circulation of subtype III variety C and D
VEE complex alphaviruses was also detected [14].
Since 2003, VEEV has been continuously isolated from febrile
patients living in Iquitos and Yurimaguas (Loreto department) and
more recently from patients living in Puerto Maldonado, (Madre
de Dios department) in Peru. During these surveillance activities,
two strains of VEEV were also isolated from an area in Ecuador
where VEE had been not previously reported. In addition, from
2005–2007, VEEV was isolated from febrile residents of
Eterazama in Cochabamba, Bolivia, providing, for the first time,
evidence that VEEV also circulates in this country. In this study,
we sought to investigate the genetic relationship among the VEEV
strains isolated in Bolivia, Ecuador and Peru, and compare them
to isolates from other countries in South America.
Materials and Methods
Study subjects
The study protocols were approved by the Ministry of Health of
the participant countries and the Naval Medical Research Center
Institutional Review Board (protocols NMRCD.2000.0006,
NMRCD.2001.0002, NMRCD.2000.0008) in compliance with
all applicable Federal regulations governing the protection of
human subjects. The study subjects were patients who presented
with a diagnosis of acute, febrile undifferentiated illness in their
home or at military or civilian outpatient clinics at the specimen
collection study sites described below. A signed consent form was
obtained from each volunteer after they were informed about the
study and a standardized questionnaire was used to obtain
demographic and clinical information from each patient at the
time of voluntary enrollment. Travel history information was also
recorded. The criteria for inclusion in the program have been
described previously and consist of fever 38uC or higher and no
more than 7 days duration accompanied by headache, myalgia, or
other nonspecific symptoms such as ocular and/or joint pain,
generalized fatigue, cough, nausea, vomiting, sore throat,
rhinnorhea, difficulty breathing, diarrhea, bloody stool, jaundice,
dizziness, disorientation, stiff neck, petecchiae, ecchymoses,
bleeding gums or nose [12,13]. During the acute phase of illness
blood samples were obtained from each patient, and when
possible, convalescent samples were obtained 10 days to 4 weeks
later for serological studies.
Study sites
Human VEEV isolates included in this study were obtained
from the specimen collection sites in Peru located in the city or
around Iquitos and Yurimaguas in the department of Loreto and
Puerto Maldonado in Madre de Dios. Iquitos is a city of about
400,000 residents located in the Amazon River basin in the
Department of Loreto approximately 120 meters above sea level.
Yurimaguas is located at the confluence of the Huallaga and
Paranapura rivers in the steamy rainforests of northeastern Peru
with a population of 63,000 habitants.
Puerto Maldonado is one of the most important cities of the
southern jungle. It sits on the banks of the Madre de Dios river,
which connects it with Rivera Alto in Bolivia and with Assis, in
Brazil (242 km). Puerto Maldonado is a city of approximately
25,000 habitants and is located about 256 meters above sea level.
VEEV isolates were also obtained from Eterazama, Cocha-
bamba department in Bolivia. Eterazama is located approximately
450 meters above sea level. At the time of the 2001 census, it had a
population of about 2,500 people.
Two VEEV strains were obtained from Shell and Puyo located
in the Pastaza province of the Amazon River basin of Ecuador.
Puyo is located approximately 950 meters above sea level and in
2006 it had a population of about 25,000 inhabitants. Shell is a
town of 5,000 people located 5 km from Puyo. Figure 1 shows the
geographic distribution of the sites with confirmed VEE cases
identified as part of this febrile surveillance study.
Virus isolation
Patient specimens were sent to the biosafety level 3 containment
laboratory at NMRCD. Sera were diluted 1:10 in Eagle’s
minimum essential medium (EMEM) supplemented with 2% fetal
bovine serum, 200 mg of streptomycin, and 200 U/ml of
penicillin. Diluted sera were then inoculated into monolayers of
confluent African green monkey kidney epithelial cells (Vero) and
Aedes albopictus mosquito (C6/36) cells. Slides were prepared from
the infected cells and an immunofluorescence assay (IFA) was
performed using polyclonal antibodies against several arboviruses
endemic in Peru [12,13,14,15,16,17]. A variety of arboviruses such
as dengue, Oropouche, Mayaro, group C, yellow fever and guaroa
were isolated from these samples, including the human VEEV
isolates listed in Table 1 that were selected for sequencing.
RNA extraction, RT, and PCR amplification
Viral RNA was extracted using the QIAamp viral RNA mini kit
(Qiagen, Valencia, CA) or Trizol reagent (Invitrogen, Carlsbad,
California) following the manufacturer’s protocols. The reverse
transcription (RT) reaction was done using 16RT buffer, 0.2 mM
dNTPs, 1 mM of primers, 80 U of RNAsin ribonuclease inhibitor
(Promega, Madison, WI), 1 mM of dithiothreitol (DTT), 200 U of
SuperScript reverse transcriptase (Invitrogen), and 5 ml (1/10
th)o f
the extracted RNA. The reactions were incubated at 42uC for
1 hr. The polymerase chain reaction (PCR) included 16 PCR
buffer, 0.2 mM dNTPs, 1 mM of primers, 3 mM of MgCl2, 2.5 U
of GoTaq DNA polymerase (Promega, Madison, WI) and 20% of
RNA. The conditions for the PCRs included incubation at 95uC
for 2 min, 35 cycles of 95uC for 30 sec, 48uC for 30 sec, 72uC for
1 min. A final extension of 72uC for 10 min was used to ensure
complete double-stranded DNA synthesis. The primers used for
the PCR amplification and sequencing reaction have been
previously described [14,18].
Author Summary
Venezuelan equine encephalitis virus (VEEV) has been
responsible for hundreds of thousands of human and
equine cases of severe disease in the Americas. In 2005–
2007, cases of Venezuelan equine encephalitis (VEE) were
diagnosed for the first time in residents of Bolivia; the
patients did not report traveling, suggesting endemic
circulation of VEEV in Bolivia. In 2001 and 2003, VEE cases
were also identified in Ecuador. We characterize recent
VEEV from Bolivia, Ecuador and Peru and compared their
relationships to strains from other parts of South America.
We found that most VEEV from Peru grouped within a
particular genetic lineage known to circulate in Panama
and Peru whereas the VEEV circulating in Ecuador belong
to a genetic lineage that circulates in Colombia and
Venezuela. Importantly, the VEEV from Madre de Dios,
Peru and Cochabamba, Bolivia belong to a new genetic
lineage. This finding could aid in the understanding of the
emergence and evolution of VEEV in South America and
underscores the need for continuous monitoring for VEEV
activity.
VEEV in Bolivia, Ecuador and Peru
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Purified PCR products were sequenced directly, and sequencing
analyses of the PCR products was performed using an Applied
Biosystems (Foster City, CA) Prism automated DNA sequencing
kit according to the manufacturer’s protocol. Deduced amino acid
sequences were aligned using the ClustalW algorithm in the
MacVector version 9.0 software package (MacVector, Inc., Cary,
NC), and the nucleotide sequences were aligned manually based
on codon positional homology and compared to VEEV sequences
from previously published studies available in the genbank
database [5,14,15,19]. Phylogenetic analyses were performed
using the neighbor joining, maximum parsimony, and maximum
likelihood algorithms implemented in the PAUP* version 4.0
software package [20,21]. The outgroup consisted of homologous
sequences of 4 major lineages of eastern equine encephalitis virus
(EEEV). For the neighbor joining analysis, the HKY85 distance
formula was used, and bootstrap analyses [22] were performed
with 1,000 replicates to place confidence values on the nodes
within trees. For the maximum parsimony analysis, the heuristic
algorithm was employed.
For maximum likelihood analysis, the general time-reversible
(GTR) model of nucleotide substitution was used, with a
proportion of 0.255 nucleotide sites being invariable and a gamma
distribution among-site rate variation (alpha shape parameter) of
0.726. The starting tree in the analysis was found using neighbor
joining, which was followed by successive rounds of tree bisection
reconstruction branch-swapping, identifying the maximum likeli-
hood substitutions parameter at each stage until the tree of highest
likelihood was found. Bootstrapping was subsequently performed
to assess the robustness of tree topologies using 1,000 replicate
neighbor joining trees under a maximum likelihood substitution
model.
Antigenic characterization
To evaluate antigenic differences between the VEEV subtype
ID Panama/Peru and Peru/Bolivia genotypes, convalescent sera
Figure 1. Geographic distribution of the sites in Ecuador, Peru, and Bolivia with confirmed cases of VEE.
doi:10.1371/journal.pntd.0000514.g001
VEEV in Bolivia, Ecuador and Peru
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Bolivia genotype) and Loreto, Peru (infected with subtype ID
Panama/Peru genotype) and Cochabamba, Bolivia (infected with
subtype ID Peru/Bolivia genotype) were tested against homolo-
gous and heterologous strains of VEEV. Most convalescent sera
were obtained 2 to 4 weeks after infection; however, one sample
was collected 7 years after VEE infection.
Samples were processed using a previously described plaque
reduction neutralization test (PRNT) [23]. Briefly, sera were heat-
inactivated at 56uC for 30 min and 2-fold dilutions were mixed
with 100 PFU of virus and incubated at 4uC overnight. The mix
was added onto a monolayer of Vero cells and incubated at 37uC
for 1 hr before adding an overlay of 0.4% of agarose in EMEM.
After 48 hr, plates were stained with 0.25% crystal violet in 20%
methanol and plaques were counted. The PRNT titer presented in
Table 2 is the reciprocal of the highest serum dilution capable of
neutralizing 80% of approximately 100 plaque-forming units
(PFU) of virus. The traditional serological criteria was used to
determine whether the viruses were antigenically distinguishable
(i.e. at least fourfold difference between the homologous and
heterologous titers of both, or one but not both of the two sera
tested) [24].
Table 1. List of VEE isolates included in the study.
Strain Location (Town, department, Country) Month/year Age Gender
OBT 4572 Eterazama, Cochabamba, Bolivia April 2005 56 Male
OBT 4574 Eterazama, Cochabamba, Bolivia April 2005 18 Male
OBT 4581 Eterazama, Cochabamba, Bolivia April 2005 51 Female
FVB 200 Eterazama, Cochabamba, Bolivia March 2006 29 Male
FVB 204 Eterazama, Cochabamba, Bolivia April 2006 21 Female
FVB 258 Eterazama, Cochabamba, Bolivia February 2007 23 Female
FSE 507 Puyo, Pastaza, Ecuador May 2001 30 Male
FSE 429 Shell, Pastaza, Ecuador June 2003 12 Male
IQD 3758 Iquitos, Loreto, Peru September 2002 19 Male
FSL 985 Iquitos, Loreto, Peru August 2003 30 Female
FSL 995 Iquitos, Loreto, Peru September 2003 20 Male
FSL 1063 Iquitos, Loreto, Peru November 2003 23 Female
FSL 1065 Iquitos, Loreto, Peru November 2003 24 Male
IQD 8361 Iquitos, Loreto, Peru October 2004 30 Male
IQD 9923 Iquitos, Loreto, Peru January 2005 42 Female
NFI 144 Iquitos, Loreto, Peru January 2005 34 Female
IQE 1568 Iquitos, Loreto, Peru June 2005 15 Male
NFI 276 Iquitos, Loreto, Peru February 2006 28 Male
IQE 2879 Iquitos, Loreto, Peru February 2006 15 Female
IQE 3485 Iquitos, Loreto, Peru March 2006 19 Female
IQE 3755 Iquitos, Loreto, Peru April 2006 25 Male
IQE 3963 Iquitos, Loreto, Peru May 2006 12 Female
NFI 413 Iquitos, Loreto, Peru June 2006 18 Male
IQE 4129 Iquitos, Loreto, Peru July 2006 11 Female
IQE 4267 Iquitos, Loreto, Peru August 2006 71 Male
IQE 5234 Iquitos, Loreto, Peru April 2007 8 Female
IQE 5244 Iquitos, Loreto, Peru April 2007 33 Male
IDA 85 Iquitos, Loreto, Peru June 2007 12 Male
FSL 1137 Yurimaguas, Loreto, Peru January 2004 37 Male
OBT 4458 Yurimaguas, Loreto, Peru January 2006 49 Male
FSL 2314 Yurimaguas, Loreto, Peru January 2006 3 Male
FSL 2649 Yurimaguas, Loreto, Peru July 2006 32 Male
FMD 320 Puerto Maldonado, Madre de Dios, Peru March 2005 39 Male
FMD 749 Puerto Maldonado, Madre de Dios, Peru January 2006 18 Male
FMD 1017 Puerto Maldonado, Madre de Dios, Peru February 2007 66 Female
FMD 1070 Puerto Maldonado, Madre de Dios, Peru February 2007 11 Male
FMD 1737 Puerto Maldonado, Madre de Dios, Peru December 2007 18 Male
FMD 1905 Puerto Maldonado, Madre de Dios, Peru February 2008 21 Female
doi:10.1371/journal.pntd.0000514.t001
VEEV in Bolivia, Ecuador and Peru
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Distribution and description of VEE cases
Human cases of VEE have been previously described in Iquitos
[12,13,14,19] and more recently in Yurimaguas [25]. However, in
2005, cases of VEE were reported for the first time in Puerto
Maldonado, Madre de Dios. Overall, between 2003–2008 VEEV
was isolated from 86 febrile patients in Iquitos, 11 patients in
Yurimaguas and 8 patients in Puerto Maldonado, Peru and the
demographic data collected from these recent VEE cases were
compared with those obtained prior to 2003 in Peru (n=50). The
main occupations of these patients were students, housewives,
farmers, soldiers, teachers among others. A total of 63% of the
confirmed cases by virus isolation were males and 37% were
females. Most of the patients in Peru with confirmed VEE
diagnosis by virus isolation were older than 15 years (n=155;
83.3%) and only a minority were children (n=31; 16.7%).
In Ecuador, VEEV was isolated from Shell and Puyo in the
Pastaza province, areas with no prior reports of VEE. The patients
were a physician (a 30 year-old male) and a student (a 12 year-old
male). These cases were reported in the Amazon basin region, not
far from the border with Peru.
In April 2005, VEEV was isolated for the first time in
Cochabamba, Bolivia from a patient with febrile illness. The
patient was a 56-year-old male agriculture worker and did not
report traveling to known VEE-endemic areas. Subsequent cases
were observed in March and April of the same year and in
February 2007. None of the patients reported traveling outside of
the Cochabamba department.
The nonspecific VEE clinical manifestations among the Bolivian,
Ecuadorian and Peruvian patients were very similar and include
fever (100%), chills (92%), malaise (97%), headache (84%),
hyporexia (79%), myalgia (79%), arthralgia (69%) among others.
Throughout thestudyperiod, only 3 patients with confirmedVEEV
infection (from Bolivia and Peru) developed neurological compli-
cations, one of which succumbed to the disease. A detailed
description of the fatal case will be described elsewhere. Figure 1
shows the geographical location of the confirmed VEE cases
included in this study.
Genetic characterization of VEEV isolates
In order to determine the genetic relationship among the new
VEEV isolatesfromBolivia,Ecuador,andPeruand thestrainsfrom
other areas in South America including Colombia and Venezuela,
RT-PCR amplifications and sequencing of the partial PE2 gene
(815 bp) were carried out. This genome region was chosen because
there is an extensive GenBank database of sequences available for
comparison, and because this area undergoes critical amino acid
substitutions that are associated with VEE epizootic/epidemic
emergence [14,15,18,26,27]. Recent VEEV strains were selected
for sequencing based on date of collection and geographic origin.
Overall, the phylogenetic trees that were generated in this study,
using neighbor joining, maximum parsimony, and maximum
likelihood methods, had identical topologies except for some
groupings between subtypes III and V (Figure 2). Twenty-four
isolates from Peru grouped with the Panama/Peru ID genotype
with strong bootstrap support, and no evidence of circulation of the
Colombia/Venezuela IDgenotype inPeruwasobserved among the
recent Peruvian isolates.
Interestingly, the 12 strains from Puerto Maldonado, Madre de
Dios in Peru and Eterazama (Cochabamba) in Bolivia formed a
distinct clade within subtype ID that is a sister to the Colombia/
Venezuela and the Peru/Panama genotypes. Sequence compar-
isons between the Panama/Peru and Bolivia/Peru ID genotype
viruses revealed about a 3% difference at the nucleotide level and
a 0.4% difference at the amino acid level whereas the Colombia/
Venezuela and Peru/Panama genotypes are known to differ by
about 5% at the nucleotide level and 0.8% at the amino acid level
[14]. A 1.7% nucleotide difference was observed between the
Colombia/Venezuela and Peru/Bolivia genotypes.
The two Ecuadorian strains that were obtained from patients in
2001 and 2003 grouped within the Colombia/Venezuela ID
genotype, which also includes the epidemic/epizootic subtype IAB
and IC strains. Previous isolates of ID genotype viruses from Ecuador
have grouped with the Southwest Colombia/Ecuador ID genotype
[5]. However, these isolates were collected on the western side of the
Andes mountains, while the two new isolates were collected from the
e a s t e r ns i d eo ft h i sm o u n t a i nr a n g e ,i nt h eA m a z o nb a s i n .
Antigenic characterization of the Panama/Peru and Peru/
Bolivia ID genotypes
Although the Panama/Peru and the new Bolivia/Peru ID
genotypesdifferbyonly3%atthe nucleotide level,weexaminedthe
possibility that they are antigenically distinguishable. To test this
possibility, convalescent sera from patients infected with either the
Panama/Peru ID genotype or the new Bolivia/Peru ID genotype
strain were tested for their ability to neutralize homologous and
heterologous viruses. The results demonstrated that the convales-
cent sera from these patients equally neutralize both genotype
strains (Table 2), suggesting that these strains are not antigenically
different. Because the convalescent sera were obtained 2 weeks to a
month after infection, we also included in the analyses serum from a
volunteer who contracted VEE infection (with the Panama/Peru
genotype strain) 7 years before. The results obtained with this serum
also failed to antigenically discriminate between the Panama/Peru
vs the Peru/Bolivia genotypes. Overall, the VEE neutralizing titers
range between 20 to 640 (Table 2).
The lack of convalescent sera from the Colombia/Venezuela
genotype strains prevented us from performing similar testing. We
did not attempt to produce antibodies in animals to test antigenic
differences.
Discussion
VEEV continues to cause sporadic outbreaks of severe febrile
disease in South America. In 2005, cases of VEE were detected for
the first time in Eterazama, Cochabamba department in Bolivia.
Table 2. Antigenic characterization of the isolates.
Virus strain (ID genotype)
Convalescent sera
(ID genotype)
OBT4581
(Peru/Bolivia)
FSL201
(Panama/Peru)
FSL205
(Panama/Peru)
FMD1278 (Peru/Bolivia) 320 320 320
FVB161 (Peru/Bolivia) 160 160 320
FMD657 (Peru/Bolivia) 20 40 40
FMD1789 (Peru/Bolivia) 640 640 640
FSL202 (Panama/Peru) #20 20 #20
FSL206 (Panama/Peru) 320 640 320
EMB 4544(*) 640 ND 640
Homologous titers (reciprocal virus isolate vs convalescent sera obtained from
the same patient) are represented in bold.
*Convalescent sera obtained 7 years after VEE infection.
ND, not done.
doi:10.1371/journal.pntd.0000514.t002
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this country, and more importantly, there was no proof that
VEEV was responsible for human illness in Bolivia. The
continuous isolation of VEEV from Bolivian (2005–2007) patients
with no report of traveling suggests endemic circulation of the
virus in Cochabamba. Because our surveillance activities in
Cochabamba, Bolivia were initiated only in 2005, it is difficult
to assess how long the virus has been present in this area. In
addition, the limited extent of our surveillance activities in Bolivia
that includes only the Beni, Cochabamba and Santa Cruz
departments may be preventing us from detecting VEEV cases
in other areas in Bolivia.
Surveillance activities in Madre de Dios, Peru began in 2004
but it was not until 2005 that the first VEE human cases were
reported. The construction of the Interoceanic Highway that
began in 2000 and is scheduled for completion in 2010 has
disrupted the ecology in Madre de Dios (where most of the
construction activities are currently undergoing) and cause an
increase in forest disturbance [28]. The highway, which creates a
coast to coast trucking route between the coastal cities of Ilo,
Matarani and Marcona in Peru and the Brazilian ports of Rio de
Janeiro and Santos, is therefore possibly causing the emergence of
new viruses in the area. In addition to the highway, gold mining
extraction practices have also intensified during recent years,
which is probably another key factor for the emergence of VEE
and other arboviruses in Madre de Dios. Only between 2000 and
2005, Peru had the world sixth highest loss of old-growth forests,
losing 224,600 hectares per year [28].
In Ecuador, VEEV was first detected in 1944 when the virus
was isolated from the blood of a sick horse [3]. In 1968–1969, a
large outbreak involving more than 30,000 equines was reported
in Ecuador, which later extended to Central America, Mexico and
Figure 2. Neighbor joining phylogenetic tree of the Venezuelan equine encephalitis virus (VEEV) complex. The tree was derived from
partial envelope glycoprotein precursor (PE2) gene sequences of recent VEEV isolates from Ecuador (green), Peru (red), and Bolivia (blue) and
previously published homologous sequences, using the neighbor joining program implemented in PAUP* version 4.0 [31]. The tree was rooted using
an outgroup comprised of 4 major lineages of eastern equine encephalitis virus [32]; the outgroup has been removed to improve resolution of the
figure. Virus strains are labeled by VEE complex subtype, abbreviated country name and year of isolation (last two digits of year only), followed by the
strain or code designation. The abbreviated country names are as follows: PA, Panama; GU, Guatemala; MX, Mexico; FL, Florida; TX, Texas; TR, Trinidad;
FG, French Guiana; VE, Venezuela; CO, Colombia; BR, Brazil; AG, Argentina; PE, Peru; EC, Ecuador; BO, Bolivia. Numbers indicate bootstrap values for
the clades to the right. Trees generated using maximum parsimony and maximum likelihood methods had identical topologies except for some
groupings between subtypes III and V.
doi:10.1371/journal.pntd.0000514.g002
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Ecuador yielded VEEV isolates that were genetically characterized
as the Southwestern Colombia/Ecuador ID genotype [5]. In our
study, surveillance activities in Ecuador yielded the isolation of two
VEEV subtype ID strains from febrile patients residing in the
Pastaza province, areas with previously unknown VEE activity.
Phylogenetic analyses revealed that these new isolates group within
the Colombia/Venezuela genotype, which apparently gives rise
periodically to the epidemic/epizootic IAB and IC strains
[14,15,18,26,27]. Due to the fact that the new isolates came from
a different geographic region (east of the Andes Mountains) than
the older Ecuadorian isolates from coastal regions makes it difficult
to assess whether the Southwestern Colombia/Ecuador ID
genotype is still circulating in Ecuador.
In Peru, VEEV subtype IAB was the cause of equine epizootics
along the Pacific coast in the 1940s, 1950s, 1969 and 1973 [7]. No
other epizootic has been reported since; however, enzootic VEE
complex alphaviruses have been continuously isolated from
mosquitoes, rodents, and humans. Most of these isolates were
obtained from Iquitos, which is an endemic area of VEEV
circulation [14,17]. Previous genetic analyses of the VEEV strains
from Peru identified two distinct ID genotypes responsible for
human illness: Colombia/Venezuela and Panama/Peru. In
addition, isolations of VEE complex subtype IIIC and IIID were
also reported; the latter being responsible for human illness in
Iquitos similar to subtype ID VEEV [14].
In this study, we sought to determine the genetic relationship of
the VEEV Peruvian strains isolated after 2003 and to determine the
genetic relationships of the new Ecuadorian and Bolivian strains of
VEEV to strains previously isolated in South America. Phylogenetic
analyses revealed that the strains from Bolivia form a new clade that
also includes the strains from Madre de Dios, Peru. This new clade
is a sister to the Colombia/Venezuela and Panama/Peru genotypes
and related genetically to the North/Central Venezuelan VEEV.
More detailed complete sequence analyses of the newly recognized
Bolivian-Peru genotype viruses and genetic comparison with IAB
and IC viruses is needed to identify potential mutations critical for
the emergence of epizootic viruses.
In summary, this study has identified a new genetic lineage of
VEE subtype ID, the Bolivia-Peru ID genotype. This information
could aid in the understanding of the emergence and evolution of
VEEV in South America. Further ecological and surveillance
activities are needed in Madre de Dios, Peru and Bolivia to
identify the vectors and reservoir host(s) involved in transmission
and to determine the public health impact and distribution of
VEEV in the region. In addition, field investigations are needed to
examine the possibility of emergence of epizootic strains of VEEV
in these areas.
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